The estimated Net Worth of Scott Braunstein is at least $2.89 Million dollars as of 5 August 2024. Scott Braunstein owns over 12,145 units of Marinus Pharmaceuticals Inc stock worth over $415,147 and over the last 9 years he sold MRNS stock worth over $226,313. In addition, he makes $2,245,680 as President, Chief Executive Officer, and Director at Marinus Pharmaceuticals Inc.
Sign up
Scott Braunstein MRNS stock SEC Form 4 insiders trading
Scott has made over 7 trades of the Marinus Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 12,145 units of MRNS stock worth $13,724 on 5 August 2024.
The largest trade he's ever made was buying 100,000 units of Marinus Pharmaceuticals Inc stock on 13 December 2019 worth over $125,000. On average, Scott trades about 4,261 units every 72 days since 2015. As of 5 August 2024 he still owns at least 298,667 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Scott Braunstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Scott Braunstein biography
Dr. Scott N. Braunstein M.D. serves as President, Chief Executive Officer, Director of the Company. He was Independent Director of the Company. Dr. Braunstein is currently an Operating Partner at Aisling Capital since 2015, and served as Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients from 2015 to 2018. Prior to Pacira, Scott served as a healthcare portfolio manager at Everpoint Asset Management from 2014 to 2015 and spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as a portfolio manager in the Global Healthcare team responsible for managing investments in pharmaceuticals, biotechnology, and medical devices from 2002 to 2014. Dr. Braunstein is currently Chairman of the Board of Directors for ArTara Therapeutics, a member of the Board of Directors for Esperion Therapeutics, and is nominated for election to the Board of Directors for Ziopharm Oncology. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine.
What is the salary of Scott Braunstein?
As the President, Chief Executive Officer, and Director of Marinus Pharmaceuticals Inc, the total compensation of Scott Braunstein at Marinus Pharmaceuticals Inc is $2,245,680. There are no executives at Marinus Pharmaceuticals Inc getting paid more.
How old is Scott Braunstein?
Scott Braunstein is 56, he's been the President, Chief Executive Officer, and Director of Marinus Pharmaceuticals Inc since 2019. There are 10 older and 3 younger executives at Marinus Pharmaceuticals Inc. The oldest executive at Marinus Pharmaceuticals Inc is Martha E. Manning, 66, who is the VP, Gen. Counsel & Sec..
What's Scott Braunstein's mailing address?
Scott's mailing address filed with the SEC is 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD RD, RADNOR, PA, 19087.
Insiders trading at Marinus Pharmaceuticals Inc
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves..., and Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.
What does Marinus Pharmaceuticals Inc do?
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
What does Marinus Pharmaceuticals Inc's logo look like?
Complete history of Scott Braunstein stock trades at Esperion Therapeutics, Marinus Pharmaceuticals Inc, Pacira BioSciences Inc, Trevena Inc, Alaunos Therapeutics Inc, Constellation Pharmaceuticals Inc, and Protara Therapeutics Inc
Marinus Pharmaceuticals Inc executives and stock owners
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Scott Braunstein,
President, Chief Executive Officer, Director -
Edward Smith,
Chief Financial Officer -
Dr. Scott N. Braunstein M.D.,
CEO, Pres & Director -
Dr. Scott Braunstein,
CEO, Pres & Director -
Edward F. Smith CPA,
Consultant -
Dr. Joseph Hulihan M.D.,
Chief Medical Officer -
Joseph Hulihan,
Chief Medical Officer -
Timothy Mayleben,
Independent Director -
Nicole Vitullo,
Chairman of the Board -
Michael Dougherty,
Independent Director -
Seth Fischer,
Independent Director -
Enrique Carrazana,
Independent Director -
Elan Ezickson,
Independent Director -
Charles Austin,
Director -
Sasha Damouni Ellis,
Vice President of Investor Relations -
Martha Manning,
Vice President, General Counsel, Secretary -
Dr. Kimberly A. McCormick Pharm.D., PharmD,
Sr. VP of Regulatory Affairs -
Sonya Weigle,
VP of HR -
Lisa Lejuwaan,
VP of Sales -
Steven E. Pfanstiel C.M.A., M.B.A.,
CFO & Treasurer -
Dr. Kimberly A. McCormick,
VP of Regulatory Affairs -
Christy Shafer,
Chief Commercial Officer -
Dr. Alex Aimetti,
Head of Scientific Affairs -
Rose McKinley,
VP of HR & Organizational Devel. -
Thomas J. Lyons,
VP of Corp., Bus. Devel. & Commercial Planning -
Martha E. Manning,
VP, Gen. Counsel & Sec. -
Stephen M Bloch,
Director -
Christopher Michael Cashman,
PRESIDENT AND CEO -
Jay Shepard,
Director -
Anand Sofinnova Venture Par...,
-
Anand Mehra,
Director -
Gail M Farfel,
Chief Clinical Dev & Reg -
Vii L P Canaan Partners Vii...,
-
Albena Patroneva,
Chief Medical Officer -
Masuoka K. Lorianne,
Chief Medical Officer -
Capital Life Sciences Inves...,
-
Christine Berni Silverstein,
-
Sara Nochur,
-
Anton Gopka,
Director -
Partners Vi, L.P.Blair Jame...,
-
Vi Associates, L.P.Blair Ja...,
-
Marvin Johnson,
-
Santiago Arroyo,
Director -
Sarah B. Noonberg,
-
Christina Shafer,
CHIEF COMMERCIAL OFFICER -
Steven Pfanstiel,
CFO AND COO